Strategic Acquisition Neuravi is now part of the Johnson & Johnson family through acquisition by Codman Neuro in 2017, with the EmboTrap II Revascularization Device CE marked and commercially available in Europe. This signals strong backing and potential access to broader distribution and sales channels within the Johnson & Johnson ecosystem.

European Footprint EmboTrap II is CE marked and commercially available in Europe, indicating established regulatory clearance and a ready market for neurovascular devices that can be upsold into European hospitals and stroke centers.

Clinical Collaboration Neuravi’s NTI initiative fosters collaboration between engineers, clinicians, and researchers to better understand clot dynamics, presenting a sales opportunity to partner with hospital research programs to demonstrate device performance and generate real-world evidence.

Product Differentiation Focused on acute ischemic stroke therapy with a revascularization device, Neuravi offers a differentiated product line that can complement or replace incumbent thrombectomy solutions in select EU centers, especially where evidence on clot behavior is valued.

Growth Potential With funding of $45M and a global footprint through acquisition, there is potential to expand adoption via strategic partnerships, clinical trials, and expanded training programs in neurointerventional suites to accelerate commercialization beyond legacy markets.